SHANGHAI, China--(BUSINESS WIRE)--HD Biosciences Inc., a China-based biology contract research organization (CRO) today announced the closing of its Series A financing. The current round was co-led by Morningside Venture and Lilly Asian Ventures and syndicated with Pfizer Venture Investments.
